Wedbush Securities Inc. Sells 1,319 Shares of Eli Lilly And Co (LLY)

Wedbush Securities Inc. reduced its stake in shares of Eli Lilly And Co (NYSE:LLY) by 16.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 6,765 shares of the company’s stock after selling 1,319 shares during the period. Wedbush Securities Inc.’s holdings in Eli Lilly And Co were worth $726,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Welch Group LLC purchased a new position in shares of Eli Lilly And Co during the third quarter valued at about $123,000. Zions Bancorporation purchased a new stake in Eli Lilly And Co in the third quarter worth about $128,000. Mainstay Capital Management LLC ADV grew its holdings in Eli Lilly And Co by 98.0% in the third quarter. Mainstay Capital Management LLC ADV now owns 1,218 shares of the company’s stock worth $131,000 after purchasing an additional 603 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in Eli Lilly And Co in the second quarter worth about $114,000. Finally, Fort L.P. purchased a new stake in Eli Lilly And Co in the second quarter worth about $121,000. 77.09% of the stock is owned by institutional investors.

Shares of Eli Lilly And Co stock opened at $114.96 on Friday. The company has a market cap of $123.43 billion, a P/E ratio of 26.86, a P/E/G ratio of 1.82 and a beta of 0.31. Eli Lilly And Co has a twelve month low of $73.69 and a twelve month high of $119.84. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.53 and a current ratio of 1.91.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings data on Tuesday, November 6th. The company reported $1.39 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.35 by $0.04. The company had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The firm’s revenue for the quarter was up 7.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.05 earnings per share. On average, research analysts anticipate that Eli Lilly And Co will post 5.58 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Shareholders of record on Thursday, November 15th will be given a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, November 14th. This represents a $2.25 annualized dividend and a yield of 1.96%. Eli Lilly And Co’s payout ratio is presently 52.57%.

A number of equities research analysts have weighed in on LLY shares. TheStreet upgraded shares of Eli Lilly And Co from a “c+” rating to a “b+” rating in a report on Tuesday, November 6th. ValuEngine upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating in a report on Monday, October 8th. JPMorgan Chase & Co. set a $123.00 price objective on shares of Eli Lilly And Co and gave the stock a “buy” rating in a report on Friday, October 5th. Cantor Fitzgerald set a $110.00 price objective on shares of Eli Lilly And Co and gave the stock a “buy” rating in a report on Monday, September 17th. Finally, SunTrust Banks upped their price objective on shares of Eli Lilly And Co from $105.00 to $123.00 and gave the stock a “buy” rating in a report on Monday, October 1st. Nine investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Eli Lilly And Co has a consensus rating of “Buy” and an average price target of $111.53.

In other Eli Lilly And Co news, major shareholder Eli & Co Lilly sold 10,059 shares of the stock in a transaction that occurred on Wednesday, September 12th. The shares were sold at an average price of $14.83, for a total value of $149,174.97. Following the transaction, the insider now directly owns 3,894,318 shares in the company, valued at $57,752,735.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 15,500 shares of the stock in a transaction that occurred on Tuesday, December 4th. The stock was sold at an average price of $119.00, for a total transaction of $1,844,500.00. Following the completion of the transaction, the insider now owns 118,015,304 shares in the company, valued at $14,043,821,176. The disclosure for this sale can be found here. Insiders sold 1,962,800 shares of company stock worth $149,601,553 over the last quarter. Insiders own 0.11% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://transcriptdaily.com/2018/12/07/wedbush-securities-inc-sells-1319-shares-of-eli-lilly-and-co-lly.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: What is an SEC Filing?

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply